Journal of Gynecologic Oncology (JGO)

Journal of Gynecologic Oncology (JGO)
  • 0.0 (0)
  • MEDICINE
  • UPDATED WEEKLY

The Journal of Gynecologic Oncology (JGO) is an official publication of the Asian Society of Gynecologic Oncology (ASGO), the Korean Society of Gynecologic Oncology (KSGO), the Japan Society of Gynecologic Oncology (JSGO), and the Society of Gynecologic Oncology of Canada (GOC).

  1. 07/06/2025

    JGO Weekly Summary (July 6, 2025)

    This episode summarizes a cross-sectional study from Central China on HPV genotype distribution and infection risk factors. Ye Chen and colleagues found that HPV52, 16, and 58 were most common, with infection peaks in young and older women. High-risk factors included diabetes, anxiety, low work intensity, and multiple sexual partners. Condom use and HPV vaccination were protective. The study advocates for integrative prevention strategies including psychosocial and metabolic health management.

    4 min

  2. 05/11/2025

    JGO Weekly Summary (May 11, 2025)

    In this episode of the JGO Podcast, we explore a recent study from Peking Union Medical College Hospital examining the role of adjuvant surgery in patients with high-risk chemorefractory or relapsed gestational choriocarcinoma who achieve complete remission following anti-PD-1 therapy. The retrospective analysis of 43 patients reveals no significant difference in survival outcomes between those who underwent surgery and those who did not, raising important questions about the necessity of surgical intervention in this setting. We discuss the implications of these findings in light of current treatment guidelines and emerging data on immunotherapy in gestational trophoblastic neoplasia.

    5 min

  3. 05/01/2025

    JGO Weekly Summary (April 29, 2025)

    This episode features an in-depth discussion of the Asian cohort analysis from the AtTEnd/ENGOT-EN7 phase III trial, which evaluated atezolizumab in combination with carboplatin and paclitaxel for advanced or recurrent endometrial carcinoma. While atezolizumab improved progression-free survival in mismatch repair-deficient tumors across both Asian and non-Asian populations, it showed no benefit—and potential harm—in mismatch repair-proficient Asian patients. The analysis also revealed a higher incidence of severe adverse events among Asians receiving atezolizumab. These findings highlight the importance of considering ethnic differences in treatment response and toxicity in future clinical trials.

    6 min

  4. 04/22/2025

    JGO Weekly Summary (April 22, 2025)

    In this episode, we review findings from the Japan subset of the DUO-E phase III trial, led by Shin Nishio and colleagues, which evaluated durvalumab with or without olaparib following chemotherapy in patients with newly diagnosed advanced or recurrent endometrial cancer. The study demonstrated a progression-free survival benefit in Japanese patients consistent with the global population, with a median of 15.1 months in the durvalumab plus olaparib arm compared to 9.5 months in the control arm. Safety outcomes were manageable and aligned with known profiles of the treatments. These results support durvalumab-based regimens as promising first-line options for Japanese patients.

    5 min

  5. 04/10/2025

    JGO Weekly Summary (April 10, 2025)

    In this episode, we discuss the final analysis of the KEYNOTE-826 subgroup study led by Dr. Yong-Man Kim, evaluating pembrolizumab plus chemotherapy with or without bevacizumab in East Asian patients with persistent, recurrent, or metastatic cervical cancer. The study demonstrated substantial improvements in progression-free and overall survival compared to placebo, with median progression-free survival reaching 18.0 months versus 10.4 months in the overall population, and 29.3 versus 10.9 months in patients with PD-L1 expression. Safety was consistent with the known profile of pembrolizumab. These findings support its use as a standard of care in this population.

    6 min

  6. 03/26/2025

    JGO Weekly Summary (March 25, 2025)

    In this episode of the Journal of Gynecologic Oncology podcast, we review a recent meta-analysis by Tianyu Zhang and colleagues titled "Role of Adjuvant Chemotherapy in Stage IC Ovarian Granulosa Cell Tumors." The study analyzed data from 12 retrospective studies involving 695 patients to evaluate whether postoperative adjuvant chemotherapy offers any benefit over observation alone. The findings revealed no significant differences in recurrence, mortality, or five-year survival outcomes between the two groups, including across subtypes and chemotherapy regimens. These results suggest limited therapeutic value of adjuvant chemotherapy in stage IC granulosa cell tumors and underscore the need for individualized treatment approaches. Role of adjuvant chemotherapy in stage IC ovarian granulosa cell tumors: a systematic review and meta-analysis

    6 min

  7. 03/19/2025

    JGO Weekly Summary (March 18, 2025)

    In this episode of the Journal of Gynecologic Oncology podcast, we discuss a study by Baldwin and colleagues titled Evaluation of the Role of Liver Metastasectomy in the Treatment of Stage IV Endometrial Cancer. Using data from the National Cancer Database, the researchers analyzed outcomes in 999 patients with metastatic endometrial cancer confined to the liver. The study found that patients who underwent both chemotherapy and surgical removal of liver metastases had improved survival compared to those who received chemotherapy alone, with a median survival of 20.1 months versus 14.6 months. While the findings suggest a potential benefit of metastasectomy, adjusted analysis did not reach statistical significance, highlighting the need for further prospective studies. Tune in to learn more about the evolving role of surgery in metastatic endometrial cancer treatment. Evaluation of the role of liver metastasectomy in the treatment of stage IV endometrial cancer

    5 min

  8. 03/11/2025

    JGO Weekly Summary (March 11, 2025)

    This episode explores a recent study on the increased risk of cardiovascular disease among adolescent and young adult survivors of cervical cancer. Using data from the Korean National Health Insurance Service, researchers found that these survivors face a 47% higher risk of cardiovascular disease compared to non-cancer controls, with those receiving chemoradiotherapy at particularly high risk for heart failure, ischemic heart disease, and venous thromboembolism. The findings highlight the need for long-term cardiovascular monitoring and preventive care in this population. Tune in to learn more about the implications for survivorship care. Increased cardiovascular disease risk among adolescent and young adult survivors of cervical cancer

    5 min
See All (37)

About

The Journal of Gynecologic Oncology (JGO) is an official publication of the Asian Society of Gynecologic Oncology (ASGO), the Korean Society of Gynecologic Oncology (KSGO), the Japan Society of Gynecologic Oncology (JSGO), and the Society of Gynecologic Oncology of Canada (GOC).

Information

  • Creator
    Journal of Gynecologic Oncology (JGO)
  • Years Active
    2024 - 2025
  • Episodes
    37
  • Rating
    Clean
  • Copyright
    © Journal of Gynecologic Oncology (JGO)
  • Show Website
    Journal of Gynecologic Oncology (JGO)